公司演示-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

投資者關系

信息披露

公司治理

股票信息

投資者查詢

電郵訂閱

公司演示

康寧傑瑞生物製藥投資人演示材料 2021-12-29
康寧傑瑞生物製藥投資人演示材料 2021-08-30
公司演示材料更新 2021-05-12
aacr poster #1660_kn046(pd-l1/ctla-4雙特異性抗體)聯合白蛋白結合型紫杉醇治療轉移性三陰乳腺癌患者的初步安全性、耐受性和療效結果 2021-04-12
2020年度業績投資人演示材料 2021-03-24
2020世界肺癌大會壁報-kn046用於治療晚期非小細胞肺癌(nsclc)患者的ⅱ期臨床研究數據 2021-02-01
2020世界肺癌大會迷妳口頭報告-kn046在罕見胸部腫瘤患者中的初步安全性和有效性結果 2021-02-01
公司演示材料更新 2021-01-21
asco-gi poster-kn046聯合放化療治療復發和轉移性食管鱗癌的初步療效和安全性數據 2021-01-18
2020 jefferies倫敦線上醫療投資峰會演示材料 2020-11-16
sitc 壁报-kn026与kn046联合治疗her2阳性实体瘤患者的安全性、耐受性和抗肿瘤活性初步结果 2020-11-12
第27屆citic clsa年度投資峰會演示材料 2020-09-22
2020 interim result investor presentation 2020-08-28
company recent development report - july 2020 2020-07-30
aacr poster #1181 - using translational tumor growth inhibition modeling approach and population pk analysis to predict efficacious doses for kn026, a her2 bispecific antibody 2020-06-22
2020 jefferies virtual healthcare conference 2020-06-02
asco poster #3021 - envafolimab (kn035) in advanced tumors with mismatch-repair deficiency 2020-05-29
asco poster #1041 - preliminary safety, efficacy and pharmacokinetics (pk) results of kn026, a her2-targeted bispecific antibody in patients (pts) with her2-positive metastatic breast cancer 2020-05-29
asco poster #3020 - the preliminary efficacy and safety data of kn046 (bispecific anti-pd-l1/ctla4) in patients failed on prior immune checkpoint inhibitors therapy 2020-05-29
using translational tumor growth inhibition modeling approach and population pk analysis to predict efficacious doses for kn026, a her2 bispecific antibody 2020-05-28
envafolimab (kn035) in advanced tumors with mismatch-repair deficiency 2020-05-28
the preliminary efficacy and safety data of kn046 in patients failed on prior immune checkpoint inhibitors therapy 2020-05-17
preliminary safety, efficacy and pharmacokinetics (pk) results of kn026, a her2 bispecific antibody in patients (pts) with her2-positive metastatic breast cancer 2020-05-17